AbbVie Inc.
Close on Nov 2, 2026Market cap $510.41BP/E 81.6Yield 2.30%
AbbVie Mavyret (glecaprevir/pibrentasvir by Year
Mavyret (glecaprevir/pibrentasvir — Hepatitis C) — Worldwide operational (constant-currency) growth YoY (%) (%)
AbbVie Mavyret (glecaprevir/pibrentasvir: -0.2% in FY2025, up 6.7 pts from a year earlier.
Where the FY2025 figure comes from
“|| Mavyret | 635 | 682 | 1,317 | 6.7 | (4.7) | 0.4 | (5.7) | (0.2)”
Source: Form 8-K (abbv-20251231xexhibit991.htm, filed 2026-02-04) ↗
Reported in Form 8-K Key Product Revenues Schedule.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Mavyret (glecaprevir/pibrentasvir — Hepatitis C) — Worldwide operational (constant-currency) growth YoY (%) (%) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | -0.2% | +6.7 pts | Form 8-K (abbv-20251231xexhibit991.htm, filed 2026-02-04) ↗ |
| FY2024 | Dec 31, 2024 | -6.9% | -1.2 pts | Form 8-K (abbv-20241231xexhibit991.htm, filed 2025-01-31) ↗ |
| FY2023 | Dec 31, 2023 | -5.7% | -1.0 pts | Form 8-K (abbv-20231231xexhibit991.htm, filed 2024-02-02) ↗ |
| FY2022 | Dec 31, 2022 | -4.7% | +6.1 pts | Form 8-K (abbv-20221231xexhibit991.htm, filed 2023-02-09) ↗ |
| FY2021 | Dec 31, 2021 | -10.8% | +16.0 pts | Form 8-K (abbv-20211231xexhibit991.htm, filed 2022-02-02) ↗ |
| FY2020 | Dec 31, 2020 | -26.8% | -10.9 pts | Form 8-K (abbv-20201231xexhibit991.htm, filed 2021-02-03) ↗ |
| FY2019 | Dec 31, 2019 | -15.9% | – | Form 8-K (abbv-20191231xexhibit9.htm, filed 2020-02-07) ↗ |
Cite this data
StockData. (2026). AbbVie Mavyret (glecaprevir/pibrentasvir (%), annual FY2019–FY2025 [Data set]. Compiled from AbbVie SEC filings and investor materials. https://stockdatahq.com/stocks/abbv/kpis/mavyret-ww-op-yoy
See every metric in the AbbVie KPI table. Data updated Oct 26, 2026.